Abstract:
:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies, and it is so popular that gross sales have rapidly grown to more than 230 billion dollars in just 6 years, with annual sales exceeding 80 billion dollars; it also became one of the five top-selling medicines in the world. Numerous clinical trials of BTK inhibitors in cancers were initiated in the last decade, and ~73 trials were intensively announced or updated with extended follow-up data in the most recent 3 years. In this review, we summarized the significant milestones in the preclinical discovery and clinical development of BTK inhibitors to better understand the clinical and commercial potential as well as the directions being taken. Furthermore, it also contributes impactful lessons regarding the discovery and development of other novel therapies.
journal_name
Leukemiajournal_title
Leukemiaauthors
Wen T,Wang J,Shi Y,Qian H,Liu Pdoi
10.1038/s41375-020-01072-6subject
Has Abstractpub_date
2020-10-29 00:00:00eissn
0887-6924issn
1476-5551pii
10.1038/s41375-020-01072-6pub_type
杂志文章,评审相关文献
LEUKEMIA文献大全abstract::To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in St Jude Total Therapy Study XV with treatment intensity based mainly on MRD levels measured during re...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.234
更新日期:2017-02-01 00:00:00
abstract::The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite tar...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-019-0684-5
更新日期:2020-06-01 00:00:00
abstract::Lack of apoptosis has been linked to prolonged survival of malignant B cells expressing bcl-2. The aim of the present study was to analyze the amount of bcl-2 protein expressed along normal human B-cell maturation and to establish the frequency of aberrant bcl-2 expression in B-cell malignancies. In normal bone marrow...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403231
更新日期:2004-03-01 00:00:00
abstract::The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2014.185
更新日期:2015-02-01 00:00:00
abstract::Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2014.93
更新日期:2014-10-01 00:00:00
abstract::From 1987 to 1990, intensive postremission chemotherapy was compared to autologous bone marrow transplant in previously untreated children with AML who received identical induction therapy with two courses of Daunorubicin (DNR) and conventional dose ARA-C (protocol AIEOP LAM 87). Overall, 121 of the 155 eligible patie...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:
更新日期:1992-01-01 00:00:00
abstract::The polymerase chain reaction (PCR) cannot be used to amplify the breakpoint in the chimaeric BCR-ABL gene in CML and acute leukaemias due to the large variation in the sites of breakpoint in the BCR gene (within a 5.8 kb region) and in the ABL gene (within a 150 kb region). The disease state is usually monitored usin...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1992-05-01 00:00:00
abstract::Mesenchymal stem cells (MSCs) are known for being multi-potent. However, they also possess anticancer properties, which has prompted efforts to adapt MSCs for anticancer therapies. However, MSCs have also been widely implicated in pathways that contribute to tumor growth. Numerous studies have been conducted to adapt ...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-018-0373-9
更新日期:2019-03-01 00:00:00
abstract::Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with littl...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-020-1002-y
更新日期:2020-08-04 00:00:00
abstract::Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2013.194
更新日期:2013-12-01 00:00:00
abstract::C-mpl ligand acts primarily as a lineage-specific hematopoietic growth factor by promoting proliferation of megakaryocyte precursors and their differentiation into megakaryocytes and platelets. In addition to the ability of c-mpl ligand to support megakaryocytic development from CD34+ precursor cells, several lines of...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:
更新日期:1999-01-01 00:00:00
abstract::Deregulated methylation of cytosine in DNA is a frequent finding in malignancy that is reflected by general genomic hypomethylation and regional hypermethylation that includes the myogenic gene Myf-3. In this study of 198 DNA samples from 186 patients with a wide range of lymphoproliferative disorders (LPD), the methy...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402080
更新日期:2001-04-01 00:00:00
abstract::Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2013.197
更新日期:2013-12-01 00:00:00
abstract::In diffuse large B-cell lymphoma (DLBCL), the clinical and biological significance of concordant and discordant bone marrow (BM) involvement have not been well investigated. We evaluated 712 de novo DLBCL patients with front-line rituximab-containing treatment, including 263 patients with positive and 449 with negativ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2017.222
更新日期:2018-02-01 00:00:00
abstract::In this study, we analyzed the targeting of the somatic hypermutation (SHM) mechanism at specific hotspot sequence motifs in the V(H) and Vkappa genes of 10 follicular lymphoma (FL) cases and the Vkappa and Vlambda genes of 11 kappa- and six lamda-light chain expressing multiple myeloma (MM) cases. These sequences wer...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402258
更新日期:2001-11-01 00:00:00
abstract::We present the long-term results of three consecutive clinical trials (Total Therapy studies 11, 12 and 13A) conducted for children with newly diagnosed acute lymphoblastic leukemia (ALL) between 1984 and 1994. In study 11 (1984-1988), the overall event-free survival rates (+/-1 s.e.) were 71.8 +/- 2.4% and 69.3 +/- 2...
journal_title:Leukemia
pub_type: 杂志文章,meta分析
doi:10.1038/sj.leu.2401938
更新日期:2000-12-01 00:00:00
abstract::The majority of neutralizing antibodies of HTLV-I are directed against linear epitopes of the envelope surface glycoprotein (gp46) in the immunodominant region 175-199. Although gp46 presents a remarkable degree of conservation, the substitution of the proline at position 192 by a serine is described for 10 isolates a...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::We have cloned two genes for cell surface molecules, capable of delivering the intracellular signals, which are modulated for their expression by Tax. One is the gamma chain of the interleukin-2 (IL-2) receptor which is suggested to be critical for IL-2-dependent growth of human T-cell leukemia virus type I (HTLV-I) i...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1989-04-01 00:00:00
abstract::We studied both serum-free colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin (TPO) levels in 14 patients with aplastic anemia (AA), 37 patients with myelodysplastic syndromes (MDS) and 23 patients with idiopathic thrombocytopenic purpura (ITP) to assess thrombopoiesis in these thrombocytopen...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401898
更新日期:2000-10-01 00:00:00
abstract::The human factor-dependent leukemia cell line UCSD/AML1 contains the t(3;3) (q21;q26) characteristic of the syndrome of acute leukemia with high platelets. The human homologue of the murine leukemia oncogene evi-1 was recently localized to chromosome 3q24-3q28 and transcription of evi-1 is a frequent event in mouse-re...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1992-05-01 00:00:00
abstract::The lysozyme (LZM) gene provides a very useful model for studies of phagocyte maturation, because its protein synthesis is increased during myelopoiesis and thus most abundant in terminally differentiated and activated phagoyctes. LZM gene expression and DNA methylation were examined in various normal and transformed ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400693
更新日期:1997-07-01 00:00:00
abstract::The t(14;18) chromosomal translocation occurs in most follicular non-Hodgkin's lymphomas and places the Bcl-2 gene on chromosome 18q21 into the immunoglobulin JH region on chromosome 14q32. This translocation can be exploited to detect clonal malignant cells bearing this genetic alteration. A polymerase chain reaction...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1993-01-01 00:00:00
abstract::Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-019-0550-5
更新日期:2019-11-01 00:00:00
abstract::HTLV-1 is an important factor involved in various diseases including adult T-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. Amount of HTLV-1 provirus integrated in human peripheral blood mononuclear cells might be a candidate for a risk factor in the manifestation of HTLV-1 assoc...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, rela...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:10.1038/sj.leu.2402599
更新日期:2002-09-01 00:00:00
abstract::We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years fol...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2011.29
更新日期:2011-06-01 00:00:00
abstract::Monitoring of BCR-ABL transcripts has become established practice in the management of chronic myeloid leukemia. However, nucleic acid amplification techniques are prone to variations which limit the reliability of real-time quantitative PCR (RQ-PCR) for clinical decision making, highlighting the need for standardizat...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404716
更新日期:2007-07-01 00:00:00
abstract::Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究
doi:10.1038/leu.2013.219
更新日期:2013-10-01 00:00:00
abstract::Alterations in the FLT3 gene, including internal tandem duplications (ITDs) and D835 mutations occur frequently in acute myelogenous leukemia. We investigated the prevalence and clinico-biological correlations of FLT3 ITDs and D835 mutations in 90 patients with acute promyelocytic leukemia (APL) receiving the AIDA pro...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402723
更新日期:2002-11-01 00:00:00